Aspirin to Target Arterial Events in Chronic Kidney Disease

Summary

This study aims to find out whether people with chronic kidney disease \[CKD\] should take low dose aspirin to reduce the risk of first heart attack or stroke (cardiovascular disease \[CVD\]). CKD is common and is associated with an increased risk of CVD.

CVD is caused by small blood clots and aspirin thins the blood to reduce the risk of such clots developing but it also increases the risk of bleeding.

Aspirin is recommended to prevent further CVD in people who have already had a first CVD event (so called secondary prevention). Here the investigators want to study the use of aspirin as primary prevention in people with CKD who have not had a CVD to prevent the first event, to assess whether the potential benefits exceed the risks.

Eligible patients will be recruited from their United Kingdom (UK) general practices and allocated by chance to be prescribed once daily low dose aspirin or usual care only. Follow-up will be for several years both electronically (for general practice, hospital and mortality data) and by annual questionnaires to ascertain CVD and bleeding events.

Conditions

• Chronic Kidney Diseases
• Cardiovascular Diseases
• Bleeding

Interventions

DRUG

Aspirin

75mg low dose non enteric coated or dispersible

Sponsors & Collaborators

• University of Nottingham

  collaborator OTHER

• University of Warwick

  collaborator OTHER

• Nottingham University Hospitals NHS Trust

  collaborator OTHER

• East Kent Hospitals University NHS Foundation Trust

  collaborator OTHER_GOV

• University of Durham

  collaborator OTHER

• Epsom and St Helier University Hospitals NHS Trust

  collaborator OTHER

• University of Southampton

  lead OTHER

Principal Investigators

• Hugh Gallagher, MD · Epsom and St Helier University Hospitals NHS Trust

• Simon Fraser, MD · University of Southampton

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-02-25

Primary Completion

2024-09-30

Completion

2025-09-23

Countries

• United Kingdom

Study Locations